# Regulatory decisions

> 145 filings were classified as regulatory decision in the last 90 days. The most recent was Tvardi Therapeutics, Inc. (TVRD) on Nov 19, 2026.

Canonical: https://massive.com/quote/sec-filings/8-k/regulatory-decisions
Latest filing: 2026-11-19 (covers the last 90 days)
Source: Massive (https://massive.com/docs/llms.txt)

## Latest filings

Newest first, the 25 most recent of 145.

- 2026-11-19 · [Tvardi Therapeutics, Inc. (TVRD)](https://massive.com/quote/tvrd.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-129948.txt)
  “Tvardi Therapeutics advances next-generation oral STAT3 inhibitor TTI-109 toward IND in inflammatory bowel disease following FDA pre-IND feedback.”
- 2026-11-19 · [Hallador Energy Company (HNRG)](https://massive.com/quote/hnrg.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/788965/0001628280-26-075099.txt)
  “On November 18, 2026, the Indiana Utility Regulatory Commission (the "IURC") issued an order approving the previously announced capacity agreement between Hallador Power Company, LLC ... and NIPSCO Generation, LLC.”
- 2026-11-18 · [CIK 0000100122](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000100122) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/100122/0000100122-26-000028.txt)
  “On November 17, 2026, the ACC approved new rates that will take effect on December 1, 2026. Provisions of the rate case decision include, but are not limited to:”
- 2026-11-18 · [CIK 0001725262](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001725262) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1725262/0001493152-26-053032.txt)
  “Tri-County and HBT have received regulatory approval from the Illinois Department of Financial and Professional Regulation and the Federal Deposit Insurance Corporation for the previously announced merger (the "Merger") of Tri-County with and into HBT, as well as for the proposed merger (the "Bank Merger") of First State Bank, the bank subsidiary of Tri-County, with and into Heartland Bank and Trust Company, the bank subsidiary of HBT.”
- 2026-11-17 · [HBT Financial, Inc. (HBT)](https://massive.com/quote/hbt.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/775215/0000775215-26-000103.txt)
  “As of November 16, 2026, all of the required regulatory approvals for the proposed transaction have been obtained.”
- 2026-11-17 · [AES Corporation (AES)](https://massive.com/quote/aes.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/874761/0001140361-26-044548.txt)
  “On November 17, 2026, the Federal Energy Regulatory Commission issued an order approving the Merger (the “FERC Order”). The FERC Order is a condition to the closing of the Merger.”
- 2026-11-17 · [Edesa Biotech, Inc. Common Shares (EDSA)](https://massive.com/quote/edsa.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1540159/0001171843-26-007511.txt)
  “On November 17, 2026, Edesa Biotech, Inc. announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome ("ARDS"). The designation follows a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products.”
- 2026-11-17 · [Alzamend Neuro, Inc. (ALZN)](https://massive.com/quote/alzn.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-014504.txt)
  “On October 15, 2026, the Company received written feedback from the FDA, in which the FDA did not support the proposed approach and indicated that efficacy and safety trials may be more appropriate to support a New Drug Application (an "NDA").”
- 2026-11-17 · [Mercantile Bank Corp (MBWM)](https://massive.com/quote/mbwm.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1042729/0001437749-26-037331.txt)
  “On November 17, 2026, Mercantile Bank Corporation (the \\"Company\\") issued a press release announcing that each of the Federal Deposit Insurance Corporation and the Michigan Department of Insurance and Financial Services has approved the merger of Eastern Michigan Bank, a wholly owned banking subsidiary of the Company, with and into Mercantile Bank, a wholly owned banking subsidiary of the Company, with Mercantile Bank as the resulting bank.”
- 2026-11-17 · [CIK 0001813452](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001813452) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1813452/0001437749-26-037415.txt)
  “In connection with the Illinois Department of Financial and Professional Regulation's ("IDFPR") review of the change of ownership application relating to the Company's Illinois cannabis license, the IDFPR requested certain revisions to the Merger Agreement.”
- 2026-11-17 · [OneMain Holdings, Inc. (OMF)](https://massive.com/quote/omf.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1584207/0001584207-26-000044.txt)
  “On November 17, 2026, OneMain Holdings, Inc. (the "Company") announced that the Utah Department of Financial Institutions (the "UDFI") and the Federal Deposit Insurance Corporation (the "FDIC") have approved, subject to customary conditions, the Company's applications to establish a Utah state-chartered and FDIC-insured industrial bank, OneMain Bank.”
- 2026-11-16 · [John Marshall Bancorp, Inc. (JMSB)](https://massive.com/quote/jmsb.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1710482/0001104659-26-127698.txt)
  “On November 16, 2026, John Marshall Bancorp, Inc. ("JMSB") and Eagle Financial Services, Inc. ("EFSI") issued a joint press release announcing that the Federal Reserve Bank of Richmond, acting on delegated authority from the Board of Governors of the Federal Reserve System, approved the application to merge Bank of Clarke with and into John Marshall Bank.”
- 2026-11-16 · [MiniMed Group, Inc. (MMED)](https://massive.com/quote/mmed.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/2062583/0001104659-26-127725.txt)
  “MiniMed announced that the U.S. Food and Drug Administration (the "FDA") has cleared the MiniMed Fit™ patch pump, MiniMed's first tubeless insulin pump... FDA clearance was received several months ahead of expectations and is expected to accelerate U.S. commercialization of this key product.”
- 2026-11-16 · [Eagle Financial Services Inc (EFSI)](https://massive.com/quote/efsi.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/880641/0001193125-26-462266.txt)
  “On November 16, 2026, Eagle Financial Services, Inc. ("EFSI") ... and John Marshall Bancorp, Inc. ("JMSB") ... issued a joint press release announcing that the Federal Reserve Bank of Richmond approved the application to merge Bank of Clarke with and into John Marshall Bank. The Federal Reserve Bank of Richmond also waived any application under the Bank Holding Company Act with respect to the eventual merger of EFSI with and into JMSB.”
- 2026-11-16 · [Pasithea Therapeutics Corp. (KTTA)](https://massive.com/quote/ktta.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-120147.txt)
  “The press release also announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for a Phase 2 trial of PAS-004 in adults with NF1-associated cutaneous neurofibromas.”
- 2026-11-16 · [Summit Therapeutics Inc. (SMMT)](https://massive.com/quote/smmt.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1599298/0001599298-26-000092.txt)
  “On November 15, 2026, Summit Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has issued a Complete Response Letter ("CRL") regarding the Biologics License Application ("BLA") for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. The CRL indicates that the BLA cannot be approved in its present form.”
- 2026-11-13 · [Tandem Diabetes Care, Inc. (TNDM)](https://massive.com/quote/tndm.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000148.txt)
  “On November 12, 2026, Tandem Diabetes Care, Inc. (the "Company") received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear (1).”
- 2026-11-13 · [NeOnc Technologies Holdings, Inc. (NTHI)](https://massive.com/quote/nthi.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1979414/0001829126-26-012414.txt)
  “On November 11, 2026, the Company issued a press release announcing that the U.S. Food and Drug Administration granted the Company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma. The meeting is scheduled for early January 2027.”
- 2026-11-12 · [International Money Express, Inc. (IMXI)](https://massive.com/quote/imxi.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1683695/0001140361-26-043232.txt)
  “The DFPI initially approved the Merger Agreement on February 11, 2026... Less than two weeks later, on August 13, 2026, the DFPI issued a letter suspending the approval of the Merger, pending further ongoing review.”
- 2026-11-12 · [Cardinal Infrastructure Group Inc. (CDNL)](https://massive.com/quote/cdnl.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/2079999/0001193125-26-456793.txt)
  “On November 10, 2026, the Federal Trade Commission informed Cardinal that it had granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the proposed acquisition of HBC.”
- 2026-11-12 · [The Western Union Company (WU)](https://massive.com/quote/wu.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1365135/0001193125-26-457046.txt)
  “On the evening of November 10, 2026, California's Department of Financial Protection and Innovation (the "DFPI") delivered unacceptable final Conditions of Approval that would have required material changes to the Company's business model, agent relationships, and long-term business strategy.”
- 2026-11-12 · [InspireMD, Inc. (NSPR)](https://massive.com/quote/nspr.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1433607/0001493152-26-051453.txt)
  “On November 12, 2026, the Company announced that the U.S. Food and Drug Administration has approved the Company's Premarket Approval Supplement for the CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization procedures.”
- 2026-11-10 · [Cingulate Inc. (CING)](https://massive.com/quote/cing.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-050870.txt)
  “On June 1, 2026, we received a CRL from the FDA regarding the NDA for CTx-1301. The CRL identified specific requests for additional chemistry, manufacturing and controls (CMC) information and did not raise any concerns regarding the clinical safety or efficacy of CTx-1301.”
- 2026-11-09 · [Aldeyra Therapeutics, Inc. (ALDX)](https://massive.com/quote/aldx.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1341235/0001193125-26-453537.txt)
  “In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations.”
- 2026-11-09 · [NovoCure Limited (NVCR)](https://massive.com/quote/nvcr.md) · Regulatory decision · [SEC filing](https://www.sec.gov/Archives/edgar/data/1645113/0001645113-26-000085.txt)
  “NovoCure announced that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune Mya prevented approval of the PMA application.”

## What these filings mean

- **Regulatory decision**: Regulatory approvals, rejections, complete response letters, or information requests from FDA, EPA, or other agencies.

## How this page works

1. Every 8-K disclosure from the last 90 days is classified, and those in the categories above are listed here.
2. One row per filing: a filing in several categories appears once.
3. Labels are assigned automatically from the filing text, so always check the linked 8-K.

## FAQ

### What is an SEC Form 8-K?

An 8-K is how a public company tells investors about a major event between its quarterly reports. Companies usually have four business days to file one.

### How recent is this regulatory decisions list?

It covers 8-K filings from the last 90 days, classified as regulatory decisions and sorted newest first. The Massive 8-K disclosures API has the full, continuously updated record.

## Live data

This page is built from the Massive 8-K disclosures endpoint. It takes one tertiary_category per request, so each category is its own call:

- `GET https://api.massive.com/stocks/filings/8-K/vX/disclosures?tertiary_category=regulatory_decision&filing_date.gte=2026-08-22&sort=filing_date.desc&limit=1000`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
